GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Piotroski F-Score

COTQF (Cotinga Pharmaceuticals) Piotroski F-Score : 0 (As of Sep. 24, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cotinga Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Cotinga Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Cotinga Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Cotinga Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Piotroski F-Score Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 3.00 2.00 2.00

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 3.00 3.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jan20) TTM:Last Year (Jan19) TTM:
Net Income was -0.703 + -0.402 + -0.407 + -0.408 = $-1.92 Mil.
Cash Flow from Operations was -0.067 + -0.179 + -0.092 + -0.055 = $-0.39 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Jan19)
to the end of this year (Jan20) was
(1.041 + 0.933 + 0.767 + 0.715 + 0.695) / 5 = $0.8302 Mil.
Total Assets at the begining of this year (Jan19) was $1.04 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.18 Mil.
Total Current Liabilities was $3.68 Mil.
Net Income was -1.24 + -0.748 + -0.381 + -0.211 = $-2.58 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Jan18)
to the end of last year (Jan19) was
(1.55 + 1.203 + 1.537 + 1.107 + 1.041) / 5 = $1.2876 Mil.
Total Assets at the begining of last year (Jan18) was $1.55 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $0.32 Mil.
Total Current Liabilities was $2.14 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cotinga Pharmaceuticals's current Net Income (TTM) was -1.92. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Cotinga Pharmaceuticals's current Cash Flow from Operations (TTM) was -0.39. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jan19)
=-1.92/1.041
=-1.8443804

ROA (Last Year)=Net Income/Total Assets (Jan18)
=-2.58/1.55
=-1.66451613

Cotinga Pharmaceuticals's return on assets of this year was -1.8443804. Cotinga Pharmaceuticals's return on assets of last year was -1.66451613. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Cotinga Pharmaceuticals's current Net Income (TTM) was -1.92. Cotinga Pharmaceuticals's current Cash Flow from Operations (TTM) was -0.39. ==> -0.39 > -1.92 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jan20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan19 to Jan20
=0/0.8302
=0

Gearing (Last Year: Jan19)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan18 to Jan19
=0/1.2876
=0

Cotinga Pharmaceuticals's gearing of this year was 0. Cotinga Pharmaceuticals's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jan20)=Total Current Assets/Total Current Liabilities
=0.175/3.677
=0.04759315

Current Ratio (Last Year: Jan19)=Total Current Assets/Total Current Liabilities
=0.315/2.137
=0.1474029

Cotinga Pharmaceuticals's current ratio of this year was 0.04759315. Cotinga Pharmaceuticals's current ratio of last year was 0.1474029. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Cotinga Pharmaceuticals's number of shares in issue this year was 21.986. Cotinga Pharmaceuticals's number of shares in issue last year was 21.986. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Cotinga Pharmaceuticals's gross margin of this year was . Cotinga Pharmaceuticals's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jan19)
=0/1.041
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jan18)
=0/1.55
=0

Cotinga Pharmaceuticals's asset turnover of this year was 0. Cotinga Pharmaceuticals's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Cotinga Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Cotinga Pharmaceuticals  (OTCPK:COTQF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Cotinga Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019